https://www.selleckchem.com/products/amg510.html
The STMB test showed to be sensitive to the signs of AD pathology and may represent a cognitive marker within the AD continuum. This study compares the safety and efficacy of a fixed dose of 4-factor prothrombin complex concentrate (4FPCC) to the FDA-approved variable dosing for reversal of warfarin-induced anticoagulation. This was a single-center, prospective, open-label, randomized controlled trial with subjects randomized to 4FPCC at a fixed dose of 1500 IU or the FDA-approved variable dosing regimen. The primary efficacy outcome (re
Like
Comment
Share
